Rohto Pharma Of Japan Open To Acquisition, Expansion In China
This article was originally published in PharmAsia News
Executive Summary
Japan's Rohto Pharma has decided to remain independent, although President Toshiaki Yoshino, just three months into the job, says he is not opposed to new acquisitions that would help Rohto expand. But he also wants to avoid the company being a takeover target and is looking to apply its pharmaceutical technology to help it deal with setbacks experienced under recent changes in the Pharmaceutical Affairs Law governing over-the-counter and mail-order drugs. He said Rohto also is expanding its operations in China. (Click here for more - a subscription may be required
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.